Patient-level meta-analysis of 23 trials (15 075 premenopausal women with ER-positive or ER-unknown early breast cancer): ovarian function suppression vs none reduced recurrence (RR 0.82), more so if confirmed premenopausal after chemotherapy; non-recurrence deaths did not rise.
Meta-analysisn = 15,075
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Electronic address: [email protected] et al. Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials